CA2489244A1 - Treatment of serious infections and septic shock - Google Patents

Treatment of serious infections and septic shock Download PDF

Info

Publication number
CA2489244A1
CA2489244A1 CA002489244A CA2489244A CA2489244A1 CA 2489244 A1 CA2489244 A1 CA 2489244A1 CA 002489244 A CA002489244 A CA 002489244A CA 2489244 A CA2489244 A CA 2489244A CA 2489244 A1 CA2489244 A1 CA 2489244A1
Authority
CA
Canada
Prior art keywords
rtd
therapy
gram
lps
septic shock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002489244A
Other languages
English (en)
French (fr)
Inventor
Christoph Ladel
Ben Newton
Harald Labischinski
Nina Brunner
Christoph Gerdes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2489244A1 publication Critical patent/CA2489244A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002489244A 2002-06-13 2003-05-30 Treatment of serious infections and septic shock Abandoned CA2489244A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10226216A DE10226216A1 (de) 2002-06-13 2002-06-13 Behandlung von schweren Infektionen und septischem Schock
DE10226216.0 2002-06-13
PCT/EP2003/005694 WO2003105883A1 (de) 2002-06-13 2003-05-30 Behandlung von schweren infektionen und septischem schock

Publications (1)

Publication Number Publication Date
CA2489244A1 true CA2489244A1 (en) 2003-12-24

Family

ID=29594458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002489244A Abandoned CA2489244A1 (en) 2002-06-13 2003-05-30 Treatment of serious infections and septic shock

Country Status (5)

Country Link
EP (1) EP1523324A1 (de)
AU (1) AU2003238175A1 (de)
CA (1) CA2489244A1 (de)
DE (1) DE10226216A1 (de)
WO (1) WO2003105883A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732239A (zh) * 2011-06-02 2014-04-16 加利福尼亚大学董事会 利用θ-防御素的炎性蛋白酶的阻断

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119070B2 (en) 2002-04-30 2006-10-10 The Regents Of The University Of California Antimicrobial theta defensins, analogs thereof, and methods of use
US20060217306A1 (en) * 2005-02-08 2006-09-28 Novozymes A/S Systemic treatment of infections with defensins
US20170035845A1 (en) * 2015-08-07 2017-02-09 The Regents Of The University Of California Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression
KR20220042129A (ko) 2019-06-26 2022-04-04 마이클 이. 셀스테드 신규한 세타 디펜신 유사체(novel theta defensin analogs)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335318B1 (en) * 1999-05-10 2002-01-01 The Regents Of The University Of California Antimicrobial theta defensins and methods of using same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103732239A (zh) * 2011-06-02 2014-04-16 加利福尼亚大学董事会 利用θ-防御素的炎性蛋白酶的阻断
CN109248310A (zh) * 2011-06-02 2019-01-22 加利福尼亚大学董事会 利用θ-防御素的炎性蛋白酶的阻断
US10603356B2 (en) 2011-06-02 2020-03-31 The Regents Of The University Of California Compositions and method for treatment of inflammatory bowel disease
CN109248310B (zh) * 2011-06-02 2022-07-01 加利福尼亚大学董事会 利用θ-防御素的炎性蛋白酶的阻断

Also Published As

Publication number Publication date
AU2003238175A1 (en) 2003-12-31
WO2003105883A1 (de) 2003-12-24
EP1523324A1 (de) 2005-04-20
DE10226216A1 (de) 2003-12-24

Similar Documents

Publication Publication Date Title
Sturm Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage
Wray et al. A cell wall component from pathogenic and non-pathogenic gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumour necrosis factor-α, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat
AU650262B2 (en) Compositions and methods for treating infections caused by organisms sensitive to beta -lactam antibiotics
US10646556B2 (en) Methods for treatment of and prophylaxis against inflammatory disorders
Liu et al. Assessment of antimicrobial and wound healing effects of Brevinin-2Ta against the bacterium Klebsiella pneumoniae in dermally-wounded rats
Xu et al. Interleukin‐33 contributes to ILC 2 activation and early inflammation‐associated lung injury during abdominal sepsis
Garzón-Tituaña et al. Granzyme A inhibition reduces inflammation and increases survival during abdominal sepsis
CN101018563A (zh) 衍生自cap18的抗菌肽
Mikasa et al. The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice
US20080234188A1 (en) Antimicrobial Peptides
Souza et al. Evaluation of the effects of ozone therapy in the treatment of intra-abdominal infection in rats
EP1691827B1 (de) Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
BR112019018593A2 (pt) fagoterapia
CN112341522A (zh) 一种抗菌肽及其应用
CA2489244A1 (en) Treatment of serious infections and septic shock
US10857201B2 (en) NNIF and nNIF-related peptides and related methods
CN116535481A (zh) 一种菲牛蛭抗菌肽rk22及其前体蛋白和应用
Koshak¹ et al. Causes of superinfections: deadly bacteria of tuberculosis
CN114478742B (zh) 一种抗幽门螺杆菌活性多肽及其应用
US20130231376A1 (en) Defensin-like molecules as novel antimicrobial agents
AU2003303953B2 (en) Antibacterial pyrazole carboxylic acid hydrazides
WEINSTEIN et al. Sulfonamide Blood Levels and Serum Antibacterial Activity: Studies of Relationships at Chemically Determined Blood Levels
AT414097B (de) Pharmazeutische zubereitung zur behandlung von schock
US11161881B2 (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
JP2020521838A (ja) 分画抗菌組成物およびその使用

Legal Events

Date Code Title Description
FZDE Dead